Financial Performance - Worldwide GAAP sales grew 44% to $282.6 million in Q4 2024, while non-GAAP sales increased 21% to $252.4 million[3] - Full year 2024 GAAP sales reached $940.2 million, a 26% increase, with non-GAAP sales growing 18% to $910.0 million[3] - Gross profit for Q4 2024 was $157.5 million, with a GAAP gross margin of 56%, up from 47% in Q4 2023[6] - GAAP net income for Q4 2024 was $0.8 million, compared to a net loss of $30.0 million in Q4 2023[6] - Total sales for the three months ended December 31, 2024, reached $282.648 million, a 44% increase compared to $196.796 million in the same period of 2023[24] - Gross profit for the twelve months ended December 31, 2024, was $489.574 million, up from $367.690 million in 2023, reflecting a significant increase in profitability[24] - Operating loss for the three months ended December 31, 2024, was $581, a substantial improvement from a loss of $35.060 million in the same period of 2023[24] - Net income for the three months ended December 31, 2024, was $755, compared to a net loss of $30.002 million in the same period of 2023[24] - Non-GAAP sales for the twelve months ended December 31, 2024, were $909.954 million, an 18% increase from $772.825 million in 2023[29] Market and Product Developments - U.S. insulin pump market saw a double-digit increase in conversions from multiple daily injections[3] - The company received FDA clearance for Control-IQ+ to include individuals with type 2 diabetes[3] - Tandem Mobi pump shipments increased quarter-over-quarter throughout 2024[3] - The company reported a 20% increase in pump sales in the United States for the three months ended December 31, 2024, totaling $98.438 million compared to $82.364 million in 2023[26] Future Projections - For 2025, the company projects full year sales between $997 million and $1.007 billion, with U.S. sales estimated at $725 million to $730 million[10] - Gross margin for 2025 is estimated to be approximately 54% for the full year[10] Research and Development - The company signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology for R&D on automated insulin delivery systems[3] - Research and development expenses for the twelve months ended December 31, 2024, were $198.877 million, up from $169.667 million in 2023, reflecting the company's commitment to innovation[24] Financial Position - Total current assets decreased to $724.491 million as of December 31, 2024, from $747.989 million in 2023, primarily due to a decline in cash and cash equivalents[22] - Total liabilities increased to $704.560 million as of December 31, 2024, compared to $639.026 million in 2023, indicating a rise in financial obligations[22] - Total stockholders' equity decreased to $263.098 million as of December 31, 2024, from $313.632 million in 2023, indicating a reduction in the company's net worth[22]

Core Insights - Tandem Diabetes Care, Inc. (TNDM) is expected to report a quarterly loss of $0.25 per share, reflecting a 7.4% increase compared to the same period last year. Revenue is forecasted at $255.18 million, indicating a year-over-year increase of 29.7% [1] Financial Projections - Analysts estimate 'Sales- Pump- United States' to be $101.47 million, representing a 23.2% increase from the previous year [4] - 'Sales- Supplies and Other- United States' is projected at $89.43 million, showing a 10.3% increase year over year [4] - 'Geographic Sales- Outside the United States' is expected to reach $59.87 million, indicating a 30.5% year-over-year change [5] - 'Geographic Sales- United States' is forecasted at $190.90 million, reflecting a 26.5% increase from the prior year [5] - 'Sales- Supplies and Other- Outside the United States' is estimated at $40.50 million, suggesting a 10% year-over-year increase [6] - 'Sales- Pump- Outside the United States' is projected to be $19.85 million, indicating a 13.3% increase year over year [6] Market Performance - Shares of Tandem Diabetes Care have declined by 10.7% over the past month, while the Zacks S&P 500 composite has decreased by 1.8% [7] - TNDM holds a Zacks Rank of 3 (Hold), suggesting it is expected to perform in line with the overall market in the near future [7]

Core Viewpoint - Tandem Diabetes Care, Inc. (TNDM) has shown strong momentum with a 45.7% increase in share price over the past year, significantly outperforming the industry and the S&P 500, indicating solid growth potential for investors [1]. Company Overview - Tandem Diabetes designs, develops, and markets products for individuals with insulin-dependent diabetes, with its flagship product being the t:slim X2 Insulin Delivery System, recognized as the smallest durable insulin pump available [2]. - The company offers automated insulin delivery systems that integrate with multiple continuous glucose monitoring (CGM) sensors, along with a web-based data management platform and a mobile app, Sugarmate, for glucose data logging and notifications [3]. Factors Favoring Share Growth - The upward trend in TNDM's share price is driven by an expanding portfolio of delivery devices and applications, including the launch of Tandem Source, which enhances market opportunities [4]. - The integration of the t:slim X2 with Dexcom G7 and Lyumjev supports the company's market expansion efforts, bolstered by a strong third-quarter performance and increasing revenues [4]. Financial Performance - In the third quarter of 2024, Tandem Diabetes achieved record quarterly sales, attributed to positive feedback on the newly launched Tandem Mobi [6]. - The company reported an adjusted gross profit of $124.6 million, reflecting a 38.9% year-over-year increase, with gross margin improving by 274 basis points to 51.1% [7]. - Tandem Diabetes raised its revenue guidance for 2024 to a range of $903-$910 million, up from the previous estimate of $885-$892 million, indicating investor optimism [8]. Future Estimates - The company anticipates an earnings per share (EPS) growth rate of 28.8% for 2025, compared to the industry's 16.5% growth rate, with a Zacks Consensus Estimate for 2025 revenues at $1.01 billion, suggesting a 10.5% increase from the previous year [12].

Tandem Diabetes Care, Inc.’s (TNDM) impressive strategic initiatives are expected to bolster growth in the upcoming quarters. A robust diabetes market provides a favorable opportunity for the company’s growth. However, concerns loom over the adverse impact of macroeconomic challenges. Moreover, the company’s heavy dependence on insulin pumps is worrisome. In the past year, this Zacks Rank #3 (Hold) company’s shares have surged 44.8% compared with 7.3% growth of the industry and a 24.7% rise of the S&P 500 c ...

Tandem Diabetes Care, Inc. (TNDM) has signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA). The partnership will focus on advancing research and development efforts on fully automated closed-loop insulin delivery systems.Tandem Diabetes’ previous work with UVA, including research related to its automated insulin delivery systems as part of the International Diabetes Closed Loop trials, has resulted in life-changing products for the diabetes communi ...

Tandem Diabetes Care, Inc. (TNDM) announced that the in-warranty users of the t:slim X2 insulin pump in Canada can now access full compatibility with both Dexcom’s (DXCM) G7 and G6 Continuous Glucose Monitoring (“CGM”) systems. This follows Health Canada’s sale authorization in July 2024, making t:slim X2 with Control-IQ technology the first and only insulin pump in Canada to be integrated with both systems.The commercial availability of this new offering reflects the decade-long partnership between the two ...

Tandem Diabetes Care, Inc. (TNDM) posted a third-quarter 2024 loss of 36 cents per share compared with the year-ago quarter’s reported loss of 38 cents. The figure beat the Zacks Consensus Estimate of a loss of 43 cents per share.On a GAAP basis, the loss was 35 cents per share compared with the year-ago loss of 51 cents.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings announcement, TNDM stock fell 2% in aftermarket trading yesterday. TNDM’s Q3 RevenuesGAAP reven ...

Financial Data and Key Metrics Changes - Q3 2024 sales reached $243 million, marking the highest quarterly sales in the company's history, with a year-over-year growth of 17% to 18% expected for the full year [19][30] - U.S. sales were $171 million, representing over 23% year-over-year growth, with total shipments reaching nearly 21,000 pumps [20][30] - Gross margin was 51% in Q3, with expectations for margin pressure related to the Mobi launch to ease by the end of 2024 [28][30] - Adjusted EBITDA turned positive at 2% of sales in Q3, with free cash flow generation of $22 million [29][30] Business Line Data and Key Metrics Changes - The U.S. market saw a return to year-over-year new pump growth, with over half of pump shipments being new to customers, primarily from multiple daily injections (MDI) users [11][12] - Outside the U.S. (OUS), sales grew 31% year-over-year to $72 million, with nearly 11,000 pumps shipped across 25 markets [27] - The company achieved a favorable mix in its business, with pumps contributing 51% of U.S. sales [20][21] Market Data and Key Metrics Changes - The company observed a higher rate of disposable pump converters compared to previous years, indicating a shift in customer demographics towards insulin pump therapy [12][13] - Customer enthusiasm for both t:slim X2 and Tandem Mobi was noted, with Mobi attracting a younger demographic [14][15] Company Strategy and Development Direction - The company aims to drive growth through an expanding product portfolio, with a focus on the Mobi platform and its integration with other technologies [10][36] - A multi-channel managed care strategy is being executed, with significant progress in the pharmacy channel and new contracting opportunities [22][23] - The company plans to enhance market access through tender wins in OUS markets and aims to support the use of ultra-rapid-acting insulin [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory, citing strong execution and positive customer feedback as key drivers [10][11] - The company anticipates continued growth in 2025, with multiple new growth drivers expected to contribute to revenue [31][32] - Management acknowledged the impact of seasonality on sales and margins, particularly in the U.S. market [34] Other Important Information - The company is focused on expanding its product offerings, including the development of new technologies and features for existing products [36][39] - Regulatory submissions for new products are underway, with a focus on expanding indications for Control-IQ technology [40][42] Q&A Session Summary Question: Can you provide more color on new patient starts in Q3 versus Q2? - Management noted a return to new start growth year-over-year, with new pumpers making up more than half of pump shipments, consistent with previous quarters [46][47] Question: Can you discuss the pharmacy contract in the context of your broader strategy? - Management highlighted the importance of the pharmacy contract as a first step in their strategy, focusing on pull-through and evaluating trends for 2025 [49][50] Question: How does your pricing strategy compare to competitors in the pharmacy channel? - Management stated that they are selective about contracts, aiming to lower patient out-of-pocket costs while ensuring economic viability compared to existing contracts [53] Question: What is the outlook for Q4 guidance? - Management explained that the Q4 guidance reflects historical seasonal trends and includes a timing shift of orders from Q3 to Q4, maintaining confidence in their projections [66][67] Question: What is the expected penetration rate for Type 2 diabetes patients? - Management indicated that they expect the penetration rate for Type 2 patients to increase significantly, potentially reaching over 25% as they begin to market directly [86][95] Question: How is the company positioned relative to market growth? - Management expressed confidence in the company's ability to grow above market rates, driven by new product launches and strategic initiatives [108]

For the quarter ended September 2024, Tandem Diabetes Care, Inc. (TNDM) reported revenue of $243.97 million, up 31.4% over the same period last year. EPS came in at -$0.36, compared to -$0.38 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $223.33 million, representing a surprise of +9.24%. The company delivered an EPS surprise of +16.28%, with the consensus EPS estimate being -$0.43.While investors closely watch year-over-year changes in headline numbers -- revenue ...

Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.28%. A quarter ago, it was expected that this company would post a loss of $0.54 per share when it actually produced a loss of $0.47, delivering a surprise of 12.96%.Over the last four quarters, the company h ...